RU2303996C2 - Вакцина и способ лечения болезней двигательных нейронов - Google Patents

Вакцина и способ лечения болезней двигательных нейронов Download PDF

Info

Publication number
RU2303996C2
RU2303996C2 RU2004120536/14A RU2004120536A RU2303996C2 RU 2303996 C2 RU2303996 C2 RU 2303996C2 RU 2004120536/14 A RU2004120536/14 A RU 2004120536/14A RU 2004120536 A RU2004120536 A RU 2004120536A RU 2303996 C2 RU2303996 C2 RU 2303996C2
Authority
RU
Russia
Prior art keywords
mice
als
disease
vaccine
glutamate
Prior art date
Application number
RU2004120536/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2004120536A (ru
Inventor
Мичал АЙЗЕНБАХ-ШВАРЦ (IL)
Мичал АЙЗЕНБАХ-ШВАРЦ
Эстер ЙОЛЕС (IL)
Эстер ЙОЛЕС
Original Assignee
Йеда Рисерч Энд Дивелопмент Ко.Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Йеда Рисерч Энд Дивелопмент Ко.Лтд. filed Critical Йеда Рисерч Энд Дивелопмент Ко.Лтд.
Publication of RU2004120536A publication Critical patent/RU2004120536A/ru
Application granted granted Critical
Publication of RU2303996C2 publication Critical patent/RU2303996C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
RU2004120536/14A 2001-12-06 2002-12-05 Вакцина и способ лечения болезней двигательных нейронов RU2303996C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33613901P 2001-12-06 2001-12-06
US60/336,139 2001-12-06

Publications (2)

Publication Number Publication Date
RU2004120536A RU2004120536A (ru) 2005-03-27
RU2303996C2 true RU2303996C2 (ru) 2007-08-10

Family

ID=23314742

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004120536/14A RU2303996C2 (ru) 2001-12-06 2002-12-05 Вакцина и способ лечения болезней двигательных нейронов

Country Status (23)

Country Link
US (1) US7351686B2 (enExample)
EP (1) EP1429800B1 (enExample)
JP (1) JP4542339B2 (enExample)
KR (1) KR20040081431A (enExample)
CN (2) CN1617736A (enExample)
AT (1) ATE422362T1 (enExample)
AU (1) AU2002353486B2 (enExample)
CA (1) CA2469092C (enExample)
CY (1) CY1109044T1 (enExample)
DE (1) DE60231131D1 (enExample)
DK (1) DK1429800T3 (enExample)
ES (1) ES2322566T3 (enExample)
HU (1) HU228207B1 (enExample)
IL (1) IL160105A0 (enExample)
IS (1) IS2670B (enExample)
MX (1) MXPA04005537A (enExample)
NO (1) NO336231B1 (enExample)
NZ (1) NZ533356A (enExample)
PL (1) PL205469B1 (enExample)
PT (1) PT1429800E (enExample)
RU (1) RU2303996C2 (enExample)
SI (1) SI1429800T1 (enExample)
WO (1) WO2003047500A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399740B2 (en) 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
WO2004060265A2 (en) * 2003-01-07 2004-07-22 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
CA2546077C (en) 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
DK1701730T3 (da) 2003-12-09 2013-11-25 Yeda Res & Dev Fremgangsmåde og vaccine omfattende copolymer 1 til behandling af psykiatriske forstyrrelser
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
CA2565819A1 (en) * 2004-05-07 2005-12-01 Peptimmune, Inc. Methods of treating disease with random copolymers
JP5241012B2 (ja) * 2005-07-15 2013-07-17 ノバルティス アーゲー Ｐａｍｐｓ、病原体関連分子パターン
CN100448481C (zh) * 2006-06-22 2009-01-07 中国科学院遗传与发育生物学研究所 xCT蛋白及其编码基因的新用途
WO2009040814A1 (en) 2007-09-24 2009-04-02 Hadasit Medical Research Services & Development Ltd Use of copolymer 1 for treatment of muscular dystrophy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
MX2014004309A (es) 2011-10-10 2015-07-06 Teva Pharma Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
US9861686B2 (en) * 2011-12-05 2018-01-09 Ben-Gurion University Of The Negev Research & Development Authority Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (ALS)
KR20140145173A (ko) * 2012-03-26 2014-12-22 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 알츠하이머 질병 진단 및 알츠하이머 질병 진행 진단용 세포 마커
EP2892353A4 (en) 2012-09-10 2016-10-26 Yeda Res & Dev INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE ILLNESSES, CNS LESIONS AND AGGREGATIVE DEMENTIA
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999041247A1 (en) * 1998-02-13 1999-08-19 Autoimmune, Inc. TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
RU2155063C1 (ru) * 1999-10-20 2000-08-27 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения
RU99106243A (ru) * 1996-09-27 2001-04-10 Гилфорд Фармасьютикалз Инк. Композиции на основе ингибитора naaladазы, способы лечения глутаматного расстройства и воздействия на активность нейронов у животных
WO2001052878A3 (en) * 2000-01-20 2002-01-24 Yeda Res & Dev The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3849650A (en) 1973-03-29 1974-11-19 Picker Corp Automatic x-ray inspection system
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
SE505316C2 (sv) * 1995-10-17 1997-08-04 Kenneth G Haglid Användning av proteinet S-100b för framställning av läkemedel för nervceller
RU2211697C2 (ru) * 1996-09-27 2003-09-10 Гилфорд Фармасьютикалз Инк. Способ лечения глутаматных расстройств
US20030108528A1 (en) 1998-05-19 2003-06-12 Michal Eisenbach-Schwartz Activated t-cells, nervous system-specific antigens and their uses
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO1999060021A2 (en) 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
EP1039929A1 (en) 1998-07-21 2000-10-04 YEDA RESEARCH AND DEVELOPMENT Co. Ltd. Activated t-cells and their uses
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
DE60116467T2 (de) 2000-06-07 2006-11-02 Yeda Research And Development Co., Ltd. Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US6835711B2 (en) * 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy
US7399740B2 (en) * 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU99106243A (ru) * 1996-09-27 2001-04-10 Гилфорд Фармасьютикалз Инк. Композиции на основе ингибитора naaladазы, способы лечения глутаматного расстройства и воздействия на активность нейронов у животных
WO1999041247A1 (en) * 1998-02-13 1999-08-19 Autoimmune, Inc. TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES
RU2155063C1 (ru) * 1999-10-20 2000-08-27 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения
WO2001052878A3 (en) * 2000-01-20 2002-01-24 Yeda Res & Dev The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
весь документ. *
весь документ. Болезни нервной системы: Руководство для врачей: В 2 т. / Под ред. Н.Н.Яхно и др. - М.: Медицина, 1995, т.2, с.218-227. Schori H. et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma // Proc Nati Acad Sci USA. 2001 Mar 13; 98(6):3398-403. Epub 2001 Mar 6, abstract PubMed. *
формула. *
формула: пп.1-3, 36-44, 72-81. *

Also Published As

Publication number Publication date
WO2003047500A2 (en) 2003-06-12
AU2002353486B2 (en) 2009-01-15
EP1429800A2 (en) 2004-06-23
PL370070A1 (en) 2005-05-16
HK1067043A1 (en) 2005-04-01
IS2670B (is) 2010-09-15
CN102151330A (zh) 2011-08-17
IL160105A0 (en) 2004-06-20
DK1429800T3 (da) 2009-04-27
HUP0500039A2 (hu) 2005-03-29
SI1429800T1 (sl) 2009-08-31
ATE422362T1 (de) 2009-02-15
NZ533356A (en) 2006-10-27
JP4542339B2 (ja) 2010-09-15
ES2322566T3 (es) 2009-06-23
HU228207B1 (hu) 2013-01-28
CA2469092A1 (en) 2003-06-12
NO336231B1 (no) 2015-06-22
PT1429800E (pt) 2009-04-27
US7351686B2 (en) 2008-04-01
IS7296A (is) 2004-06-03
KR20040081431A (ko) 2004-09-21
CY1109044T1 (el) 2014-07-02
MXPA04005537A (es) 2004-11-01
NO20042833L (no) 2004-08-12
DE60231131D1 (de) 2009-03-26
CA2469092C (en) 2013-02-19
US20050220802A1 (en) 2005-10-06
EP1429800B1 (en) 2009-02-11
CN1617736A (zh) 2005-05-18
EP1429800A4 (en) 2006-03-22
RU2004120536A (ru) 2005-03-27
AU2002353486A1 (en) 2003-06-17
WO2003047500A3 (en) 2004-03-18
CN102151330B (zh) 2017-04-12
HUP0500039A3 (en) 2010-01-28
PL205469B1 (pl) 2010-04-30
JP2005515198A (ja) 2005-05-26

Similar Documents

Publication Publication Date Title
US7351686B2 (en) Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
US9517256B2 (en) Vaccine and method for treatment of neurodegenerative diseases
JP2005515198A6 (ja) 運動ニューロン疾患を治療するためのワクチン及び方法
ES2315371T3 (es) Uso de poli-glu,tyr para terapia neuroprotectora del snc o snp.
JP5291878B2 (ja) 治療的免疫のためのコポリマー１を含む点眼ワクチン
Kipnis et al. Therapeutic vaccination for closed head injury
JP2005515198A5 (enExample)
US7399740B2 (en) Poly-Glu,Tyr for neuroprotective therapy
RU2481118C2 (ru) Вакцинотерапия неоваскуляризации сосудистой оболочки глаза
HK1067043B (en) Vaccine and use thereof for treatment of amyotrophic lateral sclerosis
IL160105A (en) Vaccine for treatment of amyotrophic lateral sclerosis (als)

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20201206